Rohto Pharmaceutical
Rohto Pharmaceutical Co Ltd is a Japanese healthcare and cosmetics manufacturer producing over-the-counter eye drops, skincare formulations, and non-prescription pharmaceuticals globally. The company manufactures eye care solutions under V Rohto and Rohto C3, alongside functional skincare products under brands including Hada Labo, Melano CC, and Dermacept. Principal revenues derive from direct product sales and wholesale distribution to retail pharmacies, drugstores, e-commerce channels, and supermarket chains across Japan, Asia, and international markets. Core end markets encompass retail consumers, eye care users, skincare shoppers, and drugstore customers globally. Rohto Pharmaceutical holds a market-leading global position in OTC eye care products and a dominant position in Asian hydrating skincare. The corporation is headquartered in Osaka, Japan, and its common stock trades on the Tokyo Stock Exchange.
5 of the funds FundTelligence covers report a position in Rohto Pharmaceutical.
- Legal name
- Rohto Pharmaceutical Co Ltd
- Sector
- Health Care
- Country
- Japan
- Funds holding it
- 5
Funds holding Rohto Pharmaceutical
- Templeton Japan Fund — Franklin Templeton · 1.01 % (full portfolio disclosed, September 2026)
- DNB Global Enhanced Small Cap — DNB · 0.03 % (full portfolio disclosed, September 2026)
- Handelsbanken Utviklede Markeder Index Criteria — Handelsbanken · 0.03 % (full portfolio disclosed, October 2026)
- KLP AksjeGlobal Small Cap Indeks — KLP · 0.02 % (partially disclosed portfolio, June 2026)
- Handelsbanken Global Index Criteria — Handelsbanken · 0.02 % (full portfolio disclosed, September 2026)